SCIENTIA ADVISORS: NEWS
Release Date: 05/29/2008Scientia Advisors Management Consultant and Managing Partner, Harry Glorikian will be a speaker at the IBC’s Annual conference Discovery2Diagnostics, October 20-22, 2008 at the Manchester Grand Hyatt in San Diego, California
Harry Glorikian will be speaking at IBC’s Annual conference Discovery2Diagnostics, October 20-22 on "Impact of DNA Microarrays on Molecular Diagnostics" session in the "Molecular Diagnostics" track.
Issues Discussed:
DNA microarrays are a powerful molecular diagnostic tool that facilitates multiplex, simultaneous analysis of tens to hundreds of markers that guide the identification of disease and its management. DNA microarrays have begun to move into mainstream clinical diagnostics. This presentation will review application areas of microarrays in molecular diagnostics, the market size, future growth prospects, key growth drivers, barriers, and other market forces such as regulatory and reimbursement challenges.
www.ibcusa.com
Harry Glorikian's experience allows him to intellectually address a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides both a unique and insightful perspective. Harry has more than 15 years of experience in the life science industry, developing and executing key strategic acquisitions and licensing arrangements which target revenue growth. Harry currently leads Scientia, which includes the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. Scientia's clients range from emerging innovators to global market leaders.
Click here to download PDF versionIssues Discussed:
DNA microarrays are a powerful molecular diagnostic tool that facilitates multiplex, simultaneous analysis of tens to hundreds of markers that guide the identification of disease and its management. DNA microarrays have begun to move into mainstream clinical diagnostics. This presentation will review application areas of microarrays in molecular diagnostics, the market size, future growth prospects, key growth drivers, barriers, and other market forces such as regulatory and reimbursement challenges.
www.ibcusa.com
Harry Glorikian's experience allows him to intellectually address a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides both a unique and insightful perspective. Harry has more than 15 years of experience in the life science industry, developing and executing key strategic acquisitions and licensing arrangements which target revenue growth. Harry currently leads Scientia, which includes the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. Scientia's clients range from emerging innovators to global market leaders.
